Elate Pharma, Musani Group’s state-of-the-art softgel encapsulation facility, is proud to announce a significant expansion in its production capacity. This strategic enhancement is a direct response to the escalating global demand for high-quality, precisely formulated softgel products across various therapeutic segments.

With an existing annual capacity of approximately 3.5 billion softules, this expansion further solidifies Elate Pharma’s position as a leading contract manufacturer. Our facility is meticulously designed and operated in strict adherence to current Good Manufacturing Practices (cGMP) and is built to comply with international regulatory agencies such as US-FDA, UK-MHRA, and TGA-Australia. This ensures that every softgel produced meets the highest standards of safety, efficacy, and consistency.

The new production lines incorporate the latest advancements in encapsulation technology, allowing for greater efficiency, reduced lead times, and enhanced flexibility in handling a diverse range of formulations, from vitamins and nutraceuticals to specialized pharmaceutical compounds. Our dedicated team of experts oversees every stage, from raw material inspection to final product packaging, guaranteeing uncompromised quality.

This investment underscores Musani Group’s commitment to innovation and its proactive approach to serving the evolving needs of the global healthcare industry. By expanding Elate Pharma’s capabilities, we are not just increasing output; we are reaffirming our promise to deliver ‘the best’ in advanced dosage forms, strengthening our partnerships and contributing to better health outcomes worldwide.